BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS), defined as intrapulmonary vasodilation, occurs in 10%-30% of cirrhotics and increases mortality. In a rat model of HPS induced by common bile duct ligation (CBDL), but not thioacetamide (TAA)-induced nonbiliary cirrhosis, lung capillary density increases, monocytes accumulate in the microvasculature, and signaling factors in the angiogenesis pathway (Akt and endothelial nitric oxide synthase [eNOS]) are activated. Pentoxifylline (PTX) directly decreases lung endothelial Akt and eNOS activation, blocks intravascular monocyte accumulation, and improves experimental HPS; we evaluated whether pulmonary angiogenesis develops in this model. METHODS: TAA- and PTX-treated animals were evaluated following CBDL. Lung angiogenesis was assessed by quantifying factor VIII-positive microvessels and levels of von Willebrand factor (vWf), vascular endothelial cadherin (VE-cadherin), and proliferating cell nuclear antigen (PCNA). Angiogenic factors including phospho-Akt, phospho-eNOS, vascular endothelial growth factor (VEGF)-A, and phospho-VEGF receptor-2 (p-VEGFR-2) were compared and monocyte accumulation was assessed. RESULTS: Following CBDL, but not TAA exposure, rats developed HPS that was temporally correlated with increased numbers of lung microvessel; increased levels of vWf, VE-cadherin and PCNA; and activation of Akt and eNOS. Angiogenesis was accompanied by increased pulmonary VEGF-A and p-VEGFR-2 levels, with VEGF-A staining in accumulated intravascular monocytes and alveolar endothelial cells. Following CBDL, PTX-treated rats had reduced numbers of microvessels, reduced lung monocyte accumulation, downregulation of pulmonary angiogenic factors, and reduced symptoms of HPS. CONCLUSIONS: A specific increase in pulmonary angiogenesis occurs as experimental HPS develops, accompanied by activation of VEGF-A-associated angiogenic pathways. PTX decreases the angiogenesis, reduces the symptoms of HPS, and downregulates VEGF-A mediated pathways.
BACKGROUND & AIMS:Hepatopulmonary syndrome (HPS), defined as intrapulmonary vasodilation, occurs in 10%-30% of cirrhotics and increases mortality. In a rat model of HPS induced by common bile duct ligation (CBDL), but not thioacetamide (TAA)-induced nonbiliary cirrhosis, lung capillary density increases, monocytes accumulate in the microvasculature, and signaling factors in the angiogenesis pathway (Akt and endothelial nitric oxide synthase [eNOS]) are activated. Pentoxifylline (PTX) directly decreases lung endothelial Akt and eNOS activation, blocks intravascular monocyte accumulation, and improves experimental HPS; we evaluated whether pulmonary angiogenesis develops in this model. METHODS: TAA- and PTX-treated animals were evaluated following CBDL. Lung angiogenesis was assessed by quantifying factor VIII-positive microvessels and levels of von Willebrand factor (vWf), vascular endothelial cadherin (VE-cadherin), and proliferating cell nuclear antigen (PCNA). Angiogenic factors including phospho-Akt, phospho-eNOS, vascular endothelial growth factor (VEGF)-A, and phospho-VEGF receptor-2 (p-VEGFR-2) were compared and monocyte accumulation was assessed. RESULTS: Following CBDL, but not TAA exposure, rats developed HPS that was temporally correlated with increased numbers of lung microvessel; increased levels of vWf, VE-cadherin and PCNA; and activation of Akt and eNOS. Angiogenesis was accompanied by increased pulmonary VEGF-A and p-VEGFR-2 levels, with VEGF-A staining in accumulated intravascular monocytes and alveolar endothelial cells. Following CBDL, PTX-treated rats had reduced numbers of microvessels, reduced lung monocyte accumulation, downregulation of pulmonary angiogenic factors, and reduced symptoms of HPS. CONCLUSIONS: A specific increase in pulmonary angiogenesis occurs as experimental HPS develops, accompanied by activation of VEGF-A-associated angiogenic pathways. PTX decreases the angiogenesis, reduces the symptoms of HPS, and downregulates VEGF-A mediated pathways.
Authors: Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; Balu K Chacko; Rakesh P Patel; Michael B Fallon Journal: J Appl Physiol (1985) Date: 2006-11-16
Authors: Lucas G Fernandez; Timothy D Le Cras; Mirta Ruiz; David K Glover; Irving L Kron; Victor E Laubach Journal: J Thorac Cardiovasc Surg Date: 2007-02 Impact factor: 5.209
Authors: Tarsila M C Freitas; Márcia C C Miguel; Ericka J D Silveira; Roseana A Freitas; Hébel C Galvão Journal: Exp Mol Pathol Date: 2005-04-25 Impact factor: 3.362
Authors: Triantafyllos Chavakis; Athanasios Athanasopoulos; Joong-Sup Rhee; Valeria Orlova; Thomas Schmidt-Wöll; Angelika Bierhaus; Andreas E May; Ilhan Celik; Peter P Nawroth; Klaus T Preissner Journal: Blood Date: 2004-09-21 Impact factor: 22.113
Authors: H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui Journal: Gut Date: 2003-09 Impact factor: 23.059
Authors: Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore Journal: Am J Respir Crit Care Med Date: 2010-09-10 Impact factor: 21.405